Metrics as of 10/13/2026, 06:39 PM (Berlin time), refresh in progress.
Geron Stock
Geron Corporation
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Harout Semerjian
- Employees
- 258
- Market cap
- $770 M
- IPO
- 31/07/1996
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked…
Geron stock: price history
1D
-1.6%
1W
-0.8%
1M
-11.1%
6M
-32.2%
YTD
-9.1%
1Y
-5.5%
2Y
-72.3%
5Y
-9.1%
10Y
-45.2%
Next earnings date
Next earnings date
04/11/2026 (in 18 days)
Volatility around earnings
~21% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Geron
Analyst assessment of Geron
PRICE TARGET LOW
US$4.00
CONSENSUS
US$5.89
MEDIAN
US$6.00
PRICE TARGET HIGH
US$8.00
0
STRONG BUY
15
BUY
7
HOLD
0
SELL
0
STRONG SELL
22
TOTAL · Buy
As of: 05/11/2025
Geron stock metrics
P/E
-12.04
P/B
3.68
EV/EBITDA
-20.05
RETURN ON EQUITY
-7.6%
NET MARGIN
-29.0%
DEBT/EQUITY
0.56
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
87.3%
FLOAT SHARES
560,064,695
AVG. DAILY VOLUME (30D)
10,232,347
Insider transactions (SEC)
Spiegel Robert J.
Spiegel Robert J.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.6%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Geron stock
What does Geron do?
Geron Corporation is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Harout Semerjian, the company employs around 258 people.
The IPO was on 31/07/1996; the stock trades on NASDAQ under the ticker GERN.
What do analysts say about Geron stock?
22 analysts rate the stock, the consensus is Buy (as of 05/11/2025).
The average price target is US$5.89, ranging from US$4.00 to US$8.00, with a median of US$6.00.
This is an external assessment, not a statement by Market Jury.
When does Geron report next?
The next earnings date is 04/11/2026.
Around past earnings, price swings were roughly 21% stronger than usual.
Does Geron pay a dividend?
No, Geron currently does not pay a dividend.
Which stocks are comparable to Geron?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Geron stock analyzed?
Clicking "Analyze stock" lets five strategies assess Geron against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.